Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Retinal protein aggregates as biomarkers in Alzheimer’s and Parkinson’s disease.

Dr Frederique J. Hart de Ruyter, MD, from Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands, talks about retinal biomarkers for neurodegeneration at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam. She discusses the promise of the retina as a future diagnostic tool for Alzheimer’s and Parkinson’s disease, by observing the aggregation of proteins present in the eye. Imaging of protein aggregates such as alpha-synuclein, TDP-43 inclusions, or hyperphosphorylated tau in the retina may be of more value to individual patients as biomarkers of disease progression instead of observing neurodegeneration in the eye which lacks discriminatory potential and diagnostic accuracy based on current knowledge. The future development of a label-free imaging technique to observe protein aggregation in the retina would allow patients to be non-invasively screened for Alzheimer’s or Parkinson’s disease pathology at the optometrist.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.